
IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials

Redeye provides a research update following IRLAB's Q2 report. We note that capital allocation and operational efficiency following the recent rights issue will be important to realize the company's pipeline value.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials](#)